Compare BVS & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | VSTM |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.9M | 470.7M |
| IPO Year | 2021 | 2012 |
| Metric | BVS | VSTM |
|---|---|---|
| Price | $8.49 | $6.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $13.50 | ★ $14.00 |
| AVG Volume (30 Days) | 222.1K | ★ 2.0M |
| Earning Date | 03-10-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $563,829,000.00 | $13,379,000.00 |
| Revenue This Year | N/A | $208.54 |
| Revenue Next Year | $7.11 | $251.40 |
| P/E Ratio | $53.65 | ★ N/A |
| Revenue Growth | 1.58 | ★ 33.79 |
| 52 Week Low | $5.81 | $4.01 |
| 52 Week High | $11.25 | $11.25 |
| Indicator | BVS | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 67.92 | 45.06 |
| Support Level | $7.59 | $6.01 |
| Resistance Level | $7.97 | $6.53 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 100.00 | 61.45 |
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.